In recent years, significant breakthroughs have occurred in blood cancer treatment, creating new possibilities and raising hopes for improved outcomes. One major stride is the development of immunotherapy, a treatment approach using the patient's own immune system to destroy cancer cells. Dr. Yilmaz, a lymphoma expert from UT Southwestern in Dallas, Texas, joins HealthTree to discuss immunotherapy and how it is already being used to treat patients with advanced disease.

Immunotherapy offers a promising avenue for patients who have exhausted conventional therapies. Among the various modalities within immunotherapy are chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. While initially approved for patients with refractory (not responding to treatment) cancer, these therapies are now being explored as frontline (initial) treatments to hopefully further improve cure rates for newly diagnosed patients.

At UT Southwestern, researchers are actively engaged in clinical trials evaluating different immunotherapies in refractory (not responding to treatment) cases and untreated patients. Moreover, targeted therapies tailored to specific molecules within tumor cells are also being studied alongside immunotherapy. This personalized approach to treatment aims to improve patient response while minimizing side effects.

Another avenue that researchers are exploring is combining and sequencing CAR T-cell therapies with bispecific antibodies, which could maximize their potential. The journey towards improved cancer treatment is multifaceted and ongoing. However, continued innovation and collaboration will achieve higher cure rates and better patient outcomes.

To learn more about DLBCL from other lymphoma specialists, watch our modules from HealthTree University.